Nasdaq Regulation



William Slattery, CFA Vice President Listing Qualifications

February 16, 2021

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

William Sattery

Division of Corporation Finance:

This is to certify that on February 11, 2021 The Nasdaq Stock Market (the "Exchange") received from Virpax Pharmaceuticals, Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following securities:

Common Stock, par value \$0.00001 per share

We further certify that the securities described above have been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,